Get started
Milestone Pharmaceuticals Inc.MM

Milestone Pharmaceuticals Inc.

2.25USDR
+0.24+11.94%
At close at Mar 27, 23:59 GMT
USD
No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

MIST chart


Full chart

MIST upcoming earnings


Next report date
≈
May 19
Report period
Q1 2025
EPS estimate
−0.22 USD
Revenue estimate
0.00 USD

Key stats


Market capitalization
‪120.05 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.72 USD
Net income (FY)
‪−41.52 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪50.79 M‬
Beta (1Y)
1.45

Employees


Employees (FY)
33
Change (1Y)
−14 −29.79%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.26 M‬ USD

About Milestone Pharmaceuticals Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Joseph G. Oliveto
Website
milestonepharma.com
Headquarters
Montréal
Founded
2003
FIGI
BBG009DR4MN8
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

Financials


Performance
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−16.00 M‬‬
‪‪−12.00 M‬‬
‪‪−8.00 M‬‬
‪‪−4.00 M‬‬
‪0.00‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−14.00 M‬‬
‪‪−10.50 M‬‬
‪‪−7.00 M‬‬
‪‪−3.50 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−14.00 M‬‬
‪‪−10.50 M‬‬
‪‪−7.00 M‬‬
‪‪−3.50 M‬‬
‪0.00‬
Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−20.00 M‬‬
‪0.00‬
‪‪20.00 M‬‬
‪‪40.00 M‬‬
‪‪60.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:May 19, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−0.28‬
‪−0.21‬
‪−0.14‬
‪−0.07‬
‪0.00‬
Actual
Estimate

MIST news



No news here

Looks like there's nothing to report right now

Reload

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of MIST is 2.25 USD — it has increased by 11.94% in the past 24 hours. Watch Milestone Pharmaceuticals Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Milestone Pharmaceuticals Inc. stocks are traded under the ticker MIST.
MIST stock has fallen by −15.19% compared to the previous week, the month change is a −0.99% fall, over the last year Milestone Pharmaceuticals Inc. has showed a 23.63% increase.
We've gathered analysts' opinions on Milestone Pharmaceuticals Inc. future price: according to them, MIST price has a max estimate of 25.00 USD and a min estimate of 2.00 USD. Watch MIST chart and read a more detailed Milestone Pharmaceuticals Inc. stock forecast: see what analysts think of Milestone Pharmaceuticals Inc. and suggest that you do with its stocks.
MIST reached its all-time high on Jun 28, 2019 with the price of 27.95 USD, and its all-time low was 1.12 USD and was reached on Jul 2, 2024. View more price dynamics on MIST chart.
See other stocks reaching their highest and lowest prices.
MIST stock is 17.24% volatile and has beta coefficient of 1.45. Track Milestone Pharmaceuticals Inc. stock price on the chart and check out the list of the most volatile stocks — is Milestone Pharmaceuticals Inc. there?
Today Milestone Pharmaceuticals Inc. has the market capitalization of ‪107.24 M‬, it has decreased by −1.92% over the last week.
Yes, you can track Milestone Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
Milestone Pharmaceuticals Inc. is going to release the next earnings report on May 19, 2025. Keep track of upcoming events with our Earnings Calendar.
MIST earnings for the last quarter are −0.19 USD per share, whereas the estimation was −0.16 USD resulting in a −21.79% surprise. The estimated earnings for the next quarter are −0.22 USD per share. See more details about Milestone Pharmaceuticals Inc. earnings.
Milestone Pharmaceuticals Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MIST net income for the last quarter is ‪−12.36 M‬ USD, while the quarter before that showed ‪−9.44 M‬ USD of net income which accounts for −30.98% change. Track more Milestone Pharmaceuticals Inc. financial stats to get the full picture.
No, MIST doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 28, 2025, the company has 33 employees. See our rating of the largest employees — is Milestone Pharmaceuticals Inc. on this list?
Like other stocks, MIST shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Milestone Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Milestone Pharmaceuticals Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Milestone Pharmaceuticals Inc. stock shows the neutral signal. See more of Milestone Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.